1. Executive Session 6:00 - 6:30
2. Introductions and Approval of DUR Board Minutes 6:30 - 6:35
   (Public Comment Prior to Board Action)

3. DVHA Pharmacy Administration Updates 6:35 - 6:40
   - Updates

4. Medical Director Update 6:40 – 6:45
   - Clinical Programs Update
   - Prescriber Comments

5. Follow-up Items from Previous Meetings 6:45 – 7:00
   - Appropriate use of Asthma controller medications

6. RetroDUR/DUR 7:00 – 7:20
   - 2016 RetroDUR Initiatives Schedule

7. Clinical Update: Drug Reviews 7:20 – 7:45
   (Public comment prior to Board action)

   Abbreviated New Drug Reviews
   - Kalydeco® Tab (ivacaftor)

   Full New Drug Reviews
   - Praluent® Inj (alirocumab)
   - Repatha® Inj (evolocumab)

8. Therapeutic Drug Classes – Periodic Review 7:45 – 8:15
   (Public comment prior to Board action)
   - Ophthalmic Antibiotics
   - Ophthalmics, Glaucoma Agents
   - Ophthalmic Anti-Inflammatory & Miscellaneous Agents
   - Ophthalmics for Allergic Conjunctivitis

9. New Managed Therapeutic Drug Classes 8:15 – 8:20
(Public comment prior to Board action)
  ▪ Iron Chelating Agents

10. Review of Newly-Developed/Revised Clinical Coverage Criteria and/or Preferred Products (Public comment prior to Board action)

11. General Announcements
   Selected FDA Safety Alerts
   
   Children's Guaifenesin Grape Liquid and Guaifenesin DM Cherry Liquid by Perrigo Company: Recall - Potential Defect with Dosage Cup

   FDA Drug Safety Communication: FDA cautions about dosing errors when switching between different oral formulations of antifungal Noxafil (posaconazole); label changes approved

   FDA Drug Safety Communication: FDA eliminates the Risk Evaluation and Mitigation Strategy (REMS) for rosiglitazone-containing diabetes medicines

12. Adjourn

   8:30